<DOC>
	<DOCNO>NCT01500070</DOCNO>
	<brief_summary>This single-arm , prospective , multi-center monitor trial recruiting patient critical limb ischemia one lesion arteries knee . The immediate long-term ( 12 month ) outcome PROMUS ELEMENT Everolimus-Eluting Stent System ( Boston Scientific ) PROMUS ELEMENT PLUS Everolimus-Eluting Stent System ( Boston Scientific ) evaluate . In 2 Belgian center , 3 German center 1 New Zealand center total 70 patient recruit . Primary endpoint primary patency 12 month , define absence restenosis ( ≥50 % stenosis ) occlusion within originally treat lesion base angiography .</brief_summary>
	<brief_title>PREVENT : Promus BTK</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>General Patient present rest pain minor tissue loss ( Rutherford class 4 5 ) Patient willing comply specify follow‐up evaluation specify time Patient &gt; 18 year old Patient understand nature procedure provide write informed consent , prior enrolment study Patient project life‐expectancy least 12 month The treat physician consider patient eligible below‐the‐knee treatment PROMUS ELEMENT Stent ( Boston Scientific ) PROMUS ELEMENT PLUS Stent ( Boston Scientific ) Male , infertile female , female child bear potential practicing acceptable method birth control negative pregnancy test within 7 day prior study procedure Angiographic Single multiple lesion minimally 70 % stenosis one infrapopliteal artery , include tibiofibular trunk A maximum two focal target lesion one infrapopliteal vessel Length lesion maximally 40 mm , allow maximally 2 plan stent implanted Target vessel diameter visually estimate &gt; 2.5mm &lt; 4.0mm Guidewire delivery system successfully traverse lesion General Patient refuse treatment Previously implant stent artery treat Failed PTA target lesion/vessel less 3 month prior study procedure The reference segment diameter suitable available stent design Untreated flow‐limiting inflow lesion Perioperative unsuccessful ipsilateral percutaneous vascular procedure treat inflow disease prior enrollment Any previous surgery target vessel ( include prior ipsilateral crural bypass ) Aneurysm target vessel Patient present renal failure , evidence serum creatinine level &gt; 2.0mg/dL Patient present platelet level normal range Non‐atherosclerothic disease result occlusion ( e.g . embolism , Buerger 's disease , vasculitis ) Severe medical comorbidities ( untreated CAD/CHF , severe COPD , metastatic malignancy , dementia , etc ) medical condition would preclude compliance study protocol 1‐year life expectancy Major distal amputation ( transmetatarsal ) study limb non‐study limb Septicemia bacteremia Any previously know coagulation disorder , include hypercoagulability Contraindication anticoagulation antiplatelet therapy Known allergy stent stent component Known allergy contrast medium adequately pre‐medicated prior study procedure Patient know hypersensitivity heparin , include patient previous incidence heparin‐induced thrombocytopenia ( HIT ) type II Currently participate another clinical research trial Angiographic evidence intra‐arterial thrombus atheroembolism inflow treatment Target lesion access perform transfemoral approach .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Claudication</keyword>
	<keyword>Drug-Eluting Stent</keyword>
	<keyword>BTK</keyword>
	<keyword>Everolimus</keyword>
	<keyword>CLI</keyword>
</DOC>